Sutro Biopharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Tables)

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2022

Commitments And Contingencies Disclosure [Abstract]

The components of lease costs, which the Company includes in operating expenses in the condensed Statements of Operations, were as follows (in thousands):


	Three Months Ended
	March 31,
	2022		2021
Operating lease cost	$	1,538	$	2,015
Short-term lease cost		21		41
Variable lease cost		424		380
Total lease costs	$	1,983	$	2,436

Schedule of Maturities of Operating Lease Liabilities

As of March 31, 2022, the maturities of the Company’s operating lease liabilities were as follows (in thousands):


Year Ending December 31,	Amount
	(in thousands)
Remaining in 2022	$	1,238
2023		8,002
2024		9,219
2025		9,533
2026		8,994
Thereafter		8,289
Total lease payments		45,275
Less: imputed interest		(12,563	)
Operating lease liabilities		32,712
Less: current portion		(1,078	)
Total lease liabilities, non-current	$	31,634